newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and for EGFR-TRACTr JANX008 in solid tumors Enrollment ongoing for JANX007 and JANX008 Update on JANX007 data and doses